Clinical Research Directory

Inclusion Criteria: 1. Age ≥ 18 years at enrollment. 2. Histologically or cytologically confirmed thyroid carcinoma that meets ≥ 1 of the following: * Radioactive-iodine-refractory differentiated thyroid carcinoma (DTC) * Medullary thyroid carcinoma (MTC) * Anaplastic or poorly differentiated thyroid carcinoma (ATC/PDTC) * Other locally advanced / metastatic thyroid malignancy deemed incurable by surgery alone. 3. Disease judged unresectable or entailing prohibitively high-morbidity surgery at baseline by a multidisciplinary thyroid-oncology board. 4. Documented molecular or immunophenotype qualifying for ≥ 1 study arm: * BRAF V600E mutation * RET gene fusion * RET activating point mutation (e.g., M918T) * NTRK1/2/3 fusion * Isolated TERT-promoter mutation with no BRAF/RET/NTRK alterations * Driver-negative / VEGFR-wild type ("triple-negative") * PD-L1 expression ≥ 1 % OR progression after prior multi-kinase inhibitor (MKI). 5. ECOG Performance Status 0-2. 6. At least one measurable lesion per RECIST v1.1 / iRECIST (MTC with calcitonin/CEA evaluable disease accepted). 7. Written informed consent obtained. Exclusion Criteria: 1. Untreated or symptomatic CNS metastases; patients with treated, stable lesions ≥ 4 weeks and off corticosteroids are eligible. 2. Pregnant or breastfeeding. Women and men of child-bearing potential must agree to effective contraception during study and for ≥ 120 days after last dose (≥ 180 days for men after dabrafenib/trametinib).